Jaguar Animal Well being displays at American Faculty of Veterinary Inner Medication (ACVIM) Discussion board June 23-25 ​​as a part of ongoing Canalevia CA1 business launch actions

Canalevia®-CA1, which obtained conditional approval from the FDA December 21, 2021 is the primary and solely therapy for chemotherapy-induced diarrhea (CID) in canines that obtain any kind of FDA approval

SAN FRANCISCO, CA / ACCESSWIRE / June 21, 2022 / Jaguar Well being, Inc. (NASDAQ: JAGX), beneath its Jaguar Animal Well being model title for the veterinary market, introduced at present that the corporate is exhibiting on the American Faculty of Veterinary Inner Medication (ACVIM) Discussion board, which takes place June 23-25, 2022 in Austin , TX, as a part of ongoing business launch actions for Canalevia-CA1 (Crofelemer Delayed Launch Tablets). Canalevia-CA1, the corporate’s FDA conditionally authorized prescription drug product for the therapy of chemotherapy-induced diarrhea (CID) in canines, is now obtainable from a number of main veterinary distributors in the US

Jaguar Animal Well being sponsors the 2 occasions beneath on the ACVIM Discussion board:

Jaguar Animal Well being presents Canalevia-CA1 at showcase quantity 521 at ACVIM Discussion board. Additional details about this occasion will be discovered on the convention web site by clicking right here.

About chemotherapy-induced diarrhea (CID) in canines

Because of the rising variety of chemotherapeutic brokers adopted by veterinarians and veterinary oncologists, chemotherapy is quick turning into probably the most extensively used most cancers therapy in veterinary medication. Research have discovered that the incidence of CID is without doubt one of the three most typical unwanted effects in canines present process most cancers therapy,1 and coping with unwanted effects reminiscent of diarrhea will be essential in sustaining profitable most cancers therapy. Greater than half of U.S. veterinarians who responded to a Jaguar-sponsored examine reported that CID disrupts their sufferers’ chemotherapy therapy plans, indicating an unmet want for an efficient CID therapy product.

About Crofelemer

Crofelemer is a brand new, oral natural medication extracted and purified from the purple bark sap, additionally referred to as “dragon blood”, by the drug Croton lechleri timber within the Amazon rainforest. Jaguar Well being’s wholly owned subsidiary, Napo Prescription drugs, has established a sustainable, truthful commerce harvesting program for crofelemer to make sure a excessive stage of high quality, ecological integrity and assist for the indigenous inhabitants. As well as, crofelemer is the lively ingredient in an FDA-approved antidiarrheal drug beneath botanical steering and indicated for the symptomatic reduction of non-infectious diarrhea in grownup human sufferers with HIV / AIDS on antiretroviral remedy.

About Canalevia®-CA1

Canalevia-CA1 (Crofelemer Delayed Launch Tablets) is the primary and solely prescription-approved product of the FDA to deal with chemotherapy-induced diarrhea (CID) in canines. Canalevia-CA1 is an oral formulation of crofelemer, an lively pharmaceutical ingredient remoted and purified from Croton lechleri tree. Canalevia-CA1 is conditionally authorized by the FDA beneath software quantity 141-552. Conditional approval permits commercialization of the product whereas Jaguar continues to collect the numerous proof of effectiveness required for full approval. Jaguar has been designated Minor Use in a Main Species (MUMS) by the FDA for Canalevia-CA1 to deal with CID in canines. The FDA has set a “small quantity” threshold for minor use in every of the seven main species lined by the MUMS Act. The brink for the small quantity is presently 70,000 for canines, which represents the biggest variety of canines that may endure from a illness or situation over the course of a 12 months and nonetheless have the use certified as a minor use.

Necessary security details about Canalevia-CA1

For oral use just for canines. Not for human use. Maintain Canalevia-CA1 (Crofelemer sustained-release tablets) in a secure place out of the attain of kids and different animals. Contact a doctor in case of unintentional ingestion of people. Don’t use in canines which have a identified hypersensitivity to crofelemer. Earlier than utilizing Canalevia-CA1, rule out infectious etiology of diarrhea. Canalevia-CA1 is a conditionally authorized drug indicated for the therapy of chemotherapy-induced diarrhea in canines. The most typical unwanted effects included decreased urge for food, decreased exercise, dehydration, stomach ache and vomiting.

Warning: Federal regulation restricts this drug to make use of by or on the orders of a licensed veterinarian. Use solely as directed. It’s a violation of federal regulation to make use of this product in a way aside from what’s said on the label.Conditionally authorized by the FDA pending an entire demonstration of efficacy beneath software numbers 141-552.

About Jaguar Well being, Jaguar Animal Well being, Napo Prescription drugs and Napo Therapeutics

Jaguar Well being, Inc. is a business pharmaceutical firm centered on growing new, natural, non-opioid and sustainably manufactured pharmaceuticals for people and animals with GI problems, together with continual, debilitating diarrhea. Jaguar Animal Well being is a commerce title for Jaguar Well being. Jaguar Well being’s wholly owned subsidiary, Napo Prescription drugs, Inc., focuses on growing and commercializing proprietary natural medicinal merchandise from vegetation responsibly harvested from rainforest areas. Our crofelemer drug candidate is topic to On aim examine, an ongoing pivotal scientific part 3 examine for the prophylaxis of diarrhea in grownup most cancers sufferers receiving focused remedy. Jaguar Well being is almost all proprietor of Napo Therapeutics SpA (f / ok / a Napo EU SpA), an Italian firm based by Jaguar Well being in Milan, Italy in 2021, which focuses on increasing entry to krofelemer in Europe.

For extra data on Jaguar Well being, go to https://jaguar.well being. For extra details about Napo Prescription drugs, go to www.napopharma.com.

Ahead-looking statements

Some statements on this press launch represent “forward-looking statements.” These embody statements about Jaguar’s expectations that it’s going to exhibit at ACVIM Discussion board 2022. In some instances, you possibly can determine forward-looking statements utilizing phrases reminiscent of “can”, “will”, “ought to”, “anticipate”, “plan”, “purpose” “,” predict “,” would “,” intention, “” paint “,” challenge “,” ponder “,” imagine “,” estimate “,” predict “,” potential “or” proceed “or the detrimental of those phrases or different related phrases. The forward-looking statements on this launch are solely predictions. Jaguar has primarily based these forward-looking statements largely on its present expectations and forecasts for future occasions. These forward-looking statements apply solely as of the date of this launch and are topic to a variety of dangers, uncertainties and assumptions, a few of which can’t be predicted or quantified and a few are past Jaguar’s management. A number of the elements that will have an effect on our precise outcomes are included within the periodic studies on Type 10-Ok and Type 10-Q that we undergo the Securities and Alternate Fee. Besides as required by relevant regulation, Jaguar doesn’t plan to publicly replace or revise any forward-looking statements contained herein, whether or not because of new data, future occasions, modified circumstances or in any other case.

1 Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or with out maropitant in canines: a potential randomized managed trial. J Small Animal Observe. 2014; 55: 391-398

Contact:

Peter Hodge
Jaguar Well being, Inc.
phodge@jaguar.well being
Jaguar-JAGX

SOURCE: Jaguar Well being, Inc.

See the supply model on accesswire.com:
https://www.accesswire.com/705796/Jaguar-Animal-Well being-Exhibiting-at-the-June-23-25-American-Faculty-of-Veterinary-Inner-Medication-ACVIM-Discussion board-as-Half- of-ongoing-commercial-launch-activities-for-Canalevia-CA1

Leave a Comment

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.